1/25/2018
`
`Apotex Corp. A Global Leader Focused on Excellence
`
`Sign up for the PharmacyTimes Newsletter
`
`Clinical
`Resources
`
`Videos
`
`Publications
`
`Contributors
`
`SHOWING CONTENT FOR:
`Community Pharmacist ▼
`Conference
`Continuing
`Coverage
`Education
`
` Search
`
` Login
`
`Back to issue
`Apotex Corp. A Global Leader Focused on
`Excellence
`
`JULY 11, 2014
`
`
`Apotex Corp., headquartered in Weston, Florida, is the US subsidiary of Apotex Inc., the largest
`Canadian-owned pharmaceutical company. Apotex Inc. produces more than 780 generic
`pharmaceutical products in approximately 2300 SKUs and exports to 121 countries globally. The
`company has successfully secured FDA approval for over 250 ANDAs—with another 375 currently in
`active development.
`
`Apotex Corp. is frequently recognized for outstanding service by customers and is ranked in the top 10
`generic pharmaceutical manufacturers according to recent IMS Health data. Apotex’s expansive
`product portfolio spans a wide range of dosage forms and therapeutic classes, including
`cardiovascular, anti-infectives, gastrointestinal, central nervous system, mental health, pain
`management, and respiratory. The company continues to diversify its product mix by adding new
`therapeutic areas and dosage forms such as transdermal patches and injectables. Earlier this year,
`Apotex launched several new products, including 2 first-tomarket generics—Budesonide Nasal Spray
`(generic equivalent to Rhinocort Aqua®) and Diclofenac Topical Solution (generic equivalent to
`Pennsaid®). With a number of first-to-file submissions and first-to-file market launches in our pipeline,
`Apotex is well positioned for growth.
`
`Commitment to Quality and Global Supply Chain Efficiencies
`
`Apotex’s highest priority is its Global Quality Program, which it considers integral to maintaining its
`strategic industry relationships. Over the past 4 years, Apotex has invested up to $150 million in new
`quality systems, technologies, and new software solutions. “Quality is something that we can never
`say we’ve done—it’s a continuous journey,” says Jeremy Desai, president and COO of Apotex Inc.
`“We have the advantage of being vertically integrated, and a large percentage of products we develop,
`we manufacture the pharmaceutical ingredient—the API,” says Desai.
`
`Investing for Tomorrow
`
`New generic products are a critical component of Apotex’s growth. Apotex has historically reinvested
`close to 20% of its revenues in research and development. More importantly, Apotex is focused on
`more than simply developing new generics; the company is also working actively to develop a broad
`portfolio of biosimilars.
`
`According to Desai, “Apotex is being built on a vision that is to provide affordable health care to
`patients across the globe.” Deeply entrenched in the company’s culture is the ability to adapt quickly
`by staying relevant in the changing health care industry landscape.
`
`Reliable Advocate and Trusted Partner
`
`Among generic manufacturers, Apotex stands alone in opposing anticompetitive patent settlements
`that delay generic competition, both by litigating against them and in advocating against them to the
`Federal Trade Commission and to Congress.
`
`IMPORTANT SAFETY INFORMATION
`CONTRAINDICATIONS
`BASAGLAR is contraindicated during episodes of
`hypoglycemia, and in patients with hypersensitivity to insulin
`glargine or one of its excipients.
`WARNINGS AND PRECAUTIONS
`BASAGLAR KwikPen® must never be shared between patients,
`The Power of One: How Partnering Can
`Enhance Your Independent Brand
`
`The Mom and Pops and stand-alones out there
`need to come together and form an alliance.
`
`ketoacidosis.
`IMPORTANT SAFETY INFORMATION
`CONTRAINDICATIONS
`BASAGLAR is contraindicated during episodes of
`hypoglycemia, and in patients with hypersensitivity to insulin
`glargine or one of its excipients.
`WARNINGS AND PRECAUTIONS
`
`Pharmacist Education
`
`Clinical features with downloadable PDFs
`
`Apotex believes that all manufacturers have a corporate citizenship responsibility to the global
`community. The company performs this responsibility through various national initiatives and
`partnerships. Apotex provides educational support to pharmacy students through a partnership with
`the National Community Pharmacists Association Foundation and supports the NACDS Foundation
`Pharmacy Partners Scholarship Program through a $1 million donation. Apotex continues to donate
`
`Exhibit 1103
`IPR2017-00807
`ARGENTUM
`http://www.pharmacytimes.com/publications/supplement/2014/generic-supplement-2014/apotex-corp-a-global-leader-focused-on-excellence
`1/3
`
`000001
`
`
`
`Apotex Corp. A Global Leader Focused on Excellence
`
`Sign up for the PharmacyTimes Newsletter
`
`Clinical
`Resources
`
`Videos
`
`Publications
`
`Contributors
`
`SHOWING CONTENT FOR:
`Community Pharmacist ▼
`Conference
`Continuing
`Coverage
`Education
`
` Search
`
` Login
`
`Back to issue
`Apotex Corp. A Global Leader Focused on
`Excellence
`
`JULY 11, 2014
`
`
`Apotex Corp., headquartered in Weston, Florida, is the US subsidiary of Apotex Inc., the largest
`Canadian-owned pharmaceutical company. Apotex Inc. produces more than 780 generic
`pharmaceutical products in approximately 2300 SKUs and exports to 121 countries globally. The
`company has successfully secured FDA approval for over 250 ANDAs—with another 375 currently in
`active development.
`
`Apotex Corp. is frequently recognized for outstanding service by customers and is ranked in the top 10
`generic pharmaceutical manufacturers according to recent IMS Health data. Apotex’s expansive
`product portfolio spans a wide range of dosage forms and therapeutic classes, including
`cardiovascular, anti-infectives, gastrointestinal, central nervous system, mental health, pain
`management, and respiratory. The company continues to diversify its product mix by adding new
`therapeutic areas and dosage forms such as transdermal patches and injectables. Earlier this year,
`Apotex launched several new products, including 2 first-tomarket generics—Budesonide Nasal Spray
`(generic equivalent to Rhinocort Aqua®) and Diclofenac Topical Solution (generic equivalent to
`Pennsaid®). With a number of first-to-file submissions and first-to-file market launches in our pipeline,
`Apotex is well positioned for growth.
`
`Commitment to Quality and Global Supply Chain Efficiencies
`
`Apotex’s highest priority is its Global Quality Program, which it considers integral to maintaining its
`strategic industry relationships. Over the past 4 years, Apotex has invested up to $150 million in new
`quality systems, technologies, and new software solutions. “Quality is something that we can never
`say we’ve done—it’s a continuous journey,” says Jeremy Desai, president and COO of Apotex Inc.
`“We have the advantage of being vertically integrated, and a large percentage of products we develop,
`we manufacture the pharmaceutical ingredient—the API,” says Desai.
`
`Investing for Tomorrow
`
`New generic products are a critical component of Apotex’s growth. Apotex has historically reinvested
`close to 20% of its revenues in research and development. More importantly, Apotex is focused on
`more than simply developing new generics; the company is also working actively to develop a broad
`portfolio of biosimilars.
`
`According to Desai, “Apotex is being built on a vision that is to provide affordable health care to
`patients across the globe.” Deeply entrenched in the company’s culture is the ability to adapt quickly
`by staying relevant in the changing health care industry landscape.
`
`Reliable Advocate and Trusted Partner
`
`Among generic manufacturers, Apotex stands alone in opposing anticompetitive patent settlements
`that delay generic competition, both by litigating against them and in advocating against them to the
`Federal Trade Commission and to Congress.
`
`IMPORTANT SAFETY INFORMATION
`CONTRAINDICATIONS
`BASAGLAR is contraindicated during episodes of
`hypoglycemia, and in patients with hypersensitivity to insulin
`glargine or one of its excipients.
`WARNINGS AND PRECAUTIONS
`BASAGLAR KwikPen® must never be shared between patients,
`The Power of One: How Partnering Can
`Enhance Your Independent Brand
`
`The Mom and Pops and stand-alones out there
`need to come together and form an alliance.
`
`ketoacidosis.
`IMPORTANT SAFETY INFORMATION
`CONTRAINDICATIONS
`BASAGLAR is contraindicated during episodes of
`hypoglycemia, and in patients with hypersensitivity to insulin
`glargine or one of its excipients.
`WARNINGS AND PRECAUTIONS
`
`Pharmacist Education
`
`Clinical features with downloadable PDFs
`
`Apotex believes that all manufacturers have a corporate citizenship responsibility to the global
`community. The company performs this responsibility through various national initiatives and
`partnerships. Apotex provides educational support to pharmacy students through a partnership with
`the National Community Pharmacists Association Foundation and supports the NACDS Foundation
`Pharmacy Partners Scholarship Program through a $1 million donation. Apotex continues to donate
`
`Exhibit 1103
`IPR2017-00807
`ARGENTUM
`http://www.pharmacytimes.com/publications/supplement/2014/generic-supplement-2014/apotex-corp-a-global-leader-focused-on-excellence
`1/3
`
`000001
`
`
`
`Apotex Corp. A Global Leader Focused on Excellence
`1/25/2018
`lifesaving medicines to developing countries to alleviate human suffering and save the lives of
`thousands of people. Apotex is committed to serving the global community by providing the highest
`quality of affordable generic medicines.
`
`For more information, visit www.apotexcorp.com.
`
`
` SHARE THIS
`
`◄
`
`0
`
` RELATED COVERAGE
`
`Clinical Use of Generic
`Injectable Drugs in
`Hospitalized Patients
`
`Generic Product News
`(September 2017)
`
`Generic Product News
`(August 2017)
`
` YOU MAY ALSO BE INTERESTED IN
`
`Clinical Use of Generic
`Injectable Drugs in
`Hospitalized Patients
`
`Generic Product News
`(September 2017)
`
`Generic Product News
`(August 2017)
`
`SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
`Personalize the information you receive by selecting targeted content and special offers.
`
`Enter your email address
`
`Sign Up
`
`RELATED SITES
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`About Pharmacy Times
`Pharmacy Times® is the #1 full-service pharmacy media resource in the
`industry. Founded in 1897, Pharmacy Times® reaches a network of over
`1.3 million retail pharmacists. Through our print, digital and live events
`channels, Pharmacy Times® provides clinically based, practical and timely
`information for the practicing pharmacist. Features and specialized
`departments cover medication errors, drug interactions, patient education,
`pharmacy technology, disease state management, patient counseling,
`product news, pharmacy law and health-system pharmacy. Pharmacy
`Times Continuing Education™ (PTCE) is accredited by the Accreditation
`Council for Pharmacy Education (ACPE) as a provider of continuing
`pharmacy education.
`
`
`
`Pharmacy & Healthcare Communications, LLC
`
`2 Clarke Drive
`
`Suite 100
`
`Cranbury, NJ 08512
`P: 609-716-7777
`
`F: 609-716-9038
`
`
`
`
`Careers Contact Us Feedback Advertise With Us Terms & Conditions Privacy Press Room
`http://www.pharmacytimes.com/publications/supplement/2014/generic-supplement-2014/apotex-corp-a-global-leader-focused-on-excellence
`
`2/3
`
`000002
`
`
`
`1/25/2018
`
`Apotex Corp. A Global Leader Focused on Excellence
`
`Copyright © 2006-2017 Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
`
`http://www.pharmacytimes.com/publications/supplement/2014/generic-supplement-2014/apotex-corp-a-global-leader-focused-on-excellence
`
`3/3
`
`000003
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
